The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial.
 
Zhi Peng
No Relationships to Disclose
 
Changzheng Li
No Relationships to Disclose
 
Xiang Wang
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Liuzhong Yang
No Relationships to Disclose
 
Xiwen Huang
No Relationships to Disclose
 
Ting Deng
No Relationships to Disclose
 
Linzhi Lu
No Relationships to Disclose
 
Hong Zong
No Relationships to Disclose
 
Jun Zhang
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Dongyan Cai
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Wei Deng
No Relationships to Disclose
 
Yin Jin
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Jianzhi Liu
Employment - RemeGen Co., Ltd.
 
Dan Feng
Employment - RemeGen Co., Ltd.
 
Jianmin Fang
Employment - RemeGen Co., Ltd.
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)